BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Alkeon Capital Management LLC

Alkeon Capital Management LLC lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 0.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,093,822 shares of the biotechnology company’s stock after selling 5,662 shares during the period. Alkeon Capital Management LLC owned 3.42% of BioCryst Pharmaceuticals worth $53,913,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BCRX. CWM LLC boosted its position in shares of BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,772 shares during the last quarter. Signaturefd LLC boosted its holdings in BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,599 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares during the period. nVerses Capital LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter worth approximately $63,000. Finally, DRW Securities LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at approximately $74,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $7.50 on Friday. The stock has a market capitalization of $1.55 billion, a P/E ratio of -12.29 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $8.88. The company has a 50 day moving average price of $7.62 and a 200 day moving average price of $7.28.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same quarter in the previous year, the business posted ($0.19) earnings per share. The firm’s revenue was up 35.1% on a year-over-year basis. On average, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on BCRX shares. Needham & Company LLC reissued a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Barclays boosted their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. JMP Securities boosted their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.